Gene therapy involves introducing a functional gene into the patient's cells to replace a missing or defective one. It has revolutionized the field of medicine and has the potential to cure a wide variety of genetic disorders. 

The two main technologies used for gene therapy are viral-based and non-viral gene editing. 

The primary advantage of viral-based gene editing is that viruses are highly efficient at transferring genes into cells. However, there are risks associated with viral-based gene therapy, such as the potential for the virus to cause immune system reactions or to integrate into the patient's DNA in harmful ways.

Non-viral gene editing, such as CRISPR, has emerged as a promising alternative to viral-based gene therapy. CRISPR is a revolutionary gene-editing technology that allows scientists to modify genes with unprecedented precision and ease. Non-viral gene editing has several advantages over viral-based gene therapy, including a lower risk of immune system reactions and less potential for the genetic material to integrate into the patient's DNA.

The quality of the reagents used for development of therapies is critical for the success. Regardless of the type of gene therapy you are developing, GenScript has an extensive solution of high-quality services and products that can fulfill you development needs. 

In this webinar, we will discuss GenScript solutions for discovery, lead generation and optimization, and pre-clinical and clinical development of gene therapies.

Learning Objectives:

• Learn about the methodologies available for in-vivo gene editing 
• Learn about the critical steps for each technology and how to best optimize
• Discover the complete toolbox of technologies available from GenScript